Charalampos Papastamos

Dr. Charalampos Papastamos

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2022 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
SSSpyridon Simantiris
Spyridon Simantiris
AAAlexios S. Antonopoulos
Alexios S. Antonopoulos
CPCharalampos Papastamos
Charalampos Papastamos
GBGeorgios Benetos
Georgios Benetos
Nikolaos KoumallosNikolaos Koumallos
Nikolaos Koumallos
Dimitris TousoulisDimitris Tousoulis
Dimitris Tousoulis

22 August 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
SSSpyridon Simantiris
Spyridon Simantiris
APAikaterini Pappa
Aikaterini Pappa
CPCharalampos Papastamos
Charalampos Papastamos
PKPanagiotis Korkonikitas
Panagiotis Korkonikitas
CACharalambos Antoniades
Charalambos Antoniades
Dimitris TousoulisDimitris Tousoulis
Dimitris Tousoulis
Perivascular adipose tissue (PVAT) interacts with the vascular wall and secretes bioactive factors which regulate vascular wall physiology. Vice versa, vascular wall inflammation affects the adjacent PVAT via paracrine signals, which induce cachexia-type morphological changes in perivascular fat. These changes can be quantified in pericoronary adipose tissue (PCAT), as an increase in PCAT attenuation in coronary computed tomography angiography images. Fat attenuation index (FAI), a novel imaging biomarker, measures PCAT attenuation around coronary artery segments and is associated with coronary artery disease presence, progression, and plaque instability. Beyond its diagnostic capacity, PCAT attenuation can also ameliorate cardiac risk stratification, thus representing an innovative prognostic biomarker of cardiovascular disease (CVD). However, technical, biological, and anatomical factors are weakly related to PCAT attenuation and cause variation in its measurement. Thus, to integrate FAI, a research tool, into clinical practice, a medical device has been designed to provide FAI values standardized for these factors. In this review, we discuss the interplay of PVAT with the vascular wall, the diagnostic and prognostic value of PCAT attenuation, and its integration as a CVD risk marker in clinical practice.